Kintsugi Therapeutics
Kintsugi Therapeutics is a Barcelona based preclinical-stage biopharmaceutical company focused on the development of innovative therapies targeting ER stress for the treatment of NASH and other pathologies.
About Kintsugi Therapeutics
Kintsugi Therapeutics, founded in 2019, is a Barcelona-based preclinical biopharmaceutical company focused on developing innovative therapies that regulate endoplasmic reticulum stress for the treatment of liver diseases and other pathologies. The company’s research particularly targets conditions such as non-alcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease (NAFLD) characterized by liver fat accumulation, inflammation, and cellular damage. By addressing the underlying mechanisms of cellular stress, Kintsugi Therapeutics aims to develop novel therapeutic solutions for significant unmet medical needs in metabolic and liver disorders.
Recently Added Startups
Tacalyx
Tacalyx creates medications that target carbohydrate antigens unique to cancer on the surface of metastatic malignant tumors for which there are no effective treatments.
We Travel Hub
We Travel Hub is a tourism-focused affiliate platform connecting travelers, content creators, merchants, and advertisers, featuring Travelfinder to monetize travel content and streamline bookings.
FrontWave Imaging
FrontWave Imaging develops supercomputing software that aids in breast cancer diagnosis. Barcelona Supercomputing Center is the parent company of Frontwave Imaging S.L.
Related Post
Cambridge Innovation Capital Commits €115 Million To Spinouts From The University Of Cambridge
CatalYm funding news – Munich-based CatalYm Secures $150 Million in Series D Round Funding
Jälle Technologies Secures €2M In Pre-Seed Round
Biotech
Tacalyx
Tacalyx creates medications that target carbohydrate antigens unique to cancer on the surface of metastatic malignant tumors for which there are no effective treatments.
Kintsugi Therapeutics
Kintsugi Therapeutics is a Barcelona based preclinical-stage biopharmaceutical company focused on the development of innovative therapies targeting ER stress for the treatment of NASH and other pathologies.
Spain
Kintsugi Therapeutics
Kintsugi Therapeutics is a Barcelona based preclinical-stage biopharmaceutical company focused on the development of innovative therapies targeting ER stress for the treatment of NASH and other pathologies.
Integra Therapeutics
Integra Therapeutics engineers next-generation gene writing tools, combining CRISPR precision with viral integrase and transposase efficiency to treat genetic diseases.